PRONTO-Peds

IRB
CHLA-19-00158
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with and Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes

To demonstrate that an ultra-fast-acting formulation of insulin lispro is non-inferior to Humalog on measures of glycemic control when administered 0 to 2 minutes before eating in combination with basal insulin.

Study Details
Clinical Trials Government Identifier
NCT03740919
Keywords
insulin ly900014, humalog, adolescents
Eligibility
Children between ages 1 to <18 years of age with an HbA1c ≥6.5% but ≤9.5%, not currently on an insulin pump, and willing to test between 4-7 times per day even if using CGM.
Does this study also recruit healthy volunteers?
No
Enrollment Status
Closed
Coordinator Contact
Debra Miller
Contact Email

dmiller@chla.usc.edu